Benjamin L. Oakes @BenjaminLOakes

CRISPR genetic medicines are often described as more “convenient” than chronic treatments like pills or injections. 𝗜 𝘁𝗵𝗶𝗻𝗸 𝘁𝗵𝗶𝘀 𝗺𝗶𝘀𝘀𝗲𝘀 𝘁𝗵𝗲 𝗽𝗼𝗶𝗻𝘁 𝗲𝗻𝘁𝗶𝗿𝗲𝗹𝘆. 𝗜𝘁 𝗶𝘀 𝗹𝗶𝗸𝗲 𝘀𝗮𝘆𝗶𝗻𝗴 𝗳𝗹𝘆𝗶𝗻𝗴 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗰𝗼𝘂𝗻𝘁𝗿𝘆 𝗶𝘀 𝗺𝗼𝗿𝗲 𝗰𝗼𝗻𝘃𝗲𝗻𝗶𝗲𝗻𝘁 𝘁𝗵𝗮𝗻 𝘄𝗮𝗹𝗸𝗶𝗻𝗴. 𝗧𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹𝗹𝘆 𝘁𝗿𝘂𝗲, 𝗯𝘂𝘁 𝘄𝗶𝗹𝗱𝗹𝘆 𝗶𝗻𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲. One is not just an easier version of the other. Flying makes the journey possible for everyone, while only a select few could ever hope to complete a cross-country trek. We see this same dynamic play out again and again in cardiovascular disease. The current standard of care asks patients to commit to chronic therapy for decades: daily pills, repeat injections, and continued persistence fails for most. 𝗜𝗻 𝗿𝗲𝗰𝗲𝗻𝘁 𝘀𝘁𝘂𝗱𝗶𝗲𝘀, 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟳𝟬% 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗲𝗿𝗲 𝗻𝗼 𝗹𝗼𝗻𝗴𝗲𝗿 𝘁𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗲𝗶𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗮𝗳𝘁𝗲𝗿 𝗼𝗻𝗹𝘆 𝗮 𝗳𝗲𝘄 𝘆𝗲𝗮𝗿𝘀. Against that backdrop, describing durable genetic medicines as simply more “convenient” does no one justice. The current chronic medication paradigm, our “sick-care” framework, simply does not work well enough for silent lifelong diseases such as CVD. 𝗪𝗲 𝗺𝘂𝘀𝘁 𝗯𝘂𝗶𝗹𝗱 𝘀𝗼𝗺𝗲𝘁𝗵𝗶𝗻𝗴 𝗯𝗲𝘁𝘁𝗲𝗿. The goal is not just fewer doses. The goal is a model of prevention that is practical for all and matched to how lifelong risk actually works. 𝗪𝗲 𝘀𝗵𝗼𝘂𝗹𝗱 𝗻𝗼𝘁 𝘀𝗲𝘁𝘁𝗹𝗲 𝗳𝗼𝗿 𝗺𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝘄𝗮𝗹𝗸 𝗲𝗮𝘀𝗶𝗲𝗿. 𝗪𝗲 𝗺𝘂𝘀𝘁 𝗯𝘂𝗶𝗹𝗱 𝘁𝗵𝗲 𝗮𝗶𝗿𝗽𝗹𝗮𝗻𝗲. I am incredibly proud that the California Institute for Regenerative Medicine is helping us make that vision a reality. Scribe recently announced that we have been awarded more than $25 million from CIRM to help advance STX-1200 for Lp(a) and STX-1400 for severely elevated triglycerides toward the clinic. This funding helps us move these programs from possibility to patients. 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗦𝗰𝗿𝗶𝗯𝗲 𝘁𝗲𝗮𝗺, 𝗮𝗻𝗱 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝘁𝗼 𝗖𝗜𝗥𝗠 𝗳𝗼𝗿 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗼𝘂𝗿 𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝘁𝗼 𝗯𝗿𝗶𝗻𝗴 𝗱𝘂𝗿𝗮𝗯𝗹𝗲 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗰𝗮𝗿𝗱𝗶𝗼𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗱𝗶𝘀𝗲𝗮𝘀𝗲.

Scribe Therapeutics @scribetx

a week ago

We’re excited to share that @CIRMnews has awarded Scribe more than $25 million through its Preclinical Development Program to accelerate the advancement of two preclinical programs targeting cardiovascular and metabolic disease. Press release in thread 📣

2 5 6 3K 0

Dr. Jennifer Doudna, Nobel laureate and Scribe co-founder, shares her vision for the future of gene editing with @bbgoriginals host @emilychangtv. Full video and article links in thread 🧵

Congrats to @scribetx and @CIRMnews! And a thoughtful analogy from @BenjaminLOakes below. If the genetic medicine could be safe enough and effective forever — we would all want the one-time genetic upgrade.

Benjamin L. Oakes @BenjaminLOakes

4 days ago

CRISPR genetic medicines are often described as more “convenient” than chronic treatments like pills or injections. 𝗜 𝘁𝗵𝗶𝗻𝗸 𝘁𝗵𝗶𝘀 𝗺𝗶𝘀𝘀𝗲𝘀 𝘁𝗵𝗲 𝗽𝗼𝗶𝗻𝘁 𝗲𝗻𝘁𝗶𝗿𝗲𝗹𝘆. 𝗜𝘁 𝗶𝘀 𝗹𝗶𝗸𝗲 𝘀𝗮𝘆𝗶𝗻𝗴 𝗳𝗹𝘆𝗶𝗻𝗴 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗰𝗼𝘂𝗻𝘁𝗿𝘆 𝗶𝘀

3 8 14 6K 4

🧬 @TheEconomist breaks down epigenetic medicine, the next frontier for CRISPR-based therapies: → How #EpigeneticEditing works → Potential safety advantages → How genes like PCSK9 that Scribe is focused on could be targeted to reduce LDL cholesterol and cardiovascular risk

In Precision Medicine Online, read about our first clinical trial for STX-1150, our novel, in vivo therapy designed to epigenetically silence PCSK9 and deliver sustained LDL-C reduction after a single dose – without permanently altering DNA. 📖 precisionmedicineonline.com/regulatory-new…

At #BIO2026, meet the BD team behind Scribe’s collaborations with leading pharma companies like Lilly and Sanofi. Set up a meeting using the @IAmBiotech portal to learn how partnerships broaden and accelerate the impact of our engineered #CRISPR tech 👇 partner.bio.org/conference/86/…

We’re excited to share that @CIRMnews has awarded Scribe more than $25 million through its Preclinical Development Program to accelerate the advancement of two preclinical programs targeting cardiovascular and metabolic disease. Press release in thread 📣

imperial.ac.uk/news/articles/…

Let’s go @scribetx!

Benjamin L. Oakes @BenjaminLOakes

a month ago

𝗧𝗼𝗱𝗮𝘆, 𝗦𝗰𝗿𝗶𝗯𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹𝗹𝘆 𝗯𝗲𝗰𝗮𝗺𝗲 𝗮 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗦𝗧𝗫-𝟭𝟭𝟱𝟬, a novel 𝘪𝘯 𝘷𝘪𝘷𝘰 epigenetic CRISPR therapy designed to

5 7 29 6K 6

Latest preclinical data from ASGCT 2026 suggest the company is pushing gene editing toward safer, longer-lasting preventive medicine. vist.ly/55ec2 #longevity #geneediting #preventivemedicine #crispr #geroscience @scribetx

Nearly 20 years ago, researchers discovered something fascinating: some people are naturally protected from heart attacks because one of their PCSK9 genes is turned off, leading to low cholesterol from birth. That observation sparked a simple but ambitious question: can we give that same protection to others? Results from the Heart-2 Phase 1 trial released today show early clinical evidence that could open the door to new possibilities. These are results in 35 people and we have a lot left to learn. But, the results could potentially mean an entirely different way of treating high cholesterol — one infusion, lifelong cholesterol lowering. See the thinking behind this approach: lilly.com/news/stories/t…

Epidemics has arrived to reduce LDL permanently but reversibly Brilliant presentation by Ben Oakes @ProfKausikRay @ProfSNicholls @BenjaminLOakes @scribetx @EASCongress @society_eas

#EASCongress2026 has kicked off! A late-breaking oral presentation from our CEO @BenjaminLOakes will showcase preclinical data for STX-1150, our epigenetic silencing therapy that’s designed for durable LDL-C reduction & now in the clinic. Thanks to @EASCongress for featuring it!

𝗧𝗼𝗱𝗮𝘆, 𝗦𝗰𝗿𝗶𝗯𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹𝗹𝘆 𝗯𝗲𝗰𝗮𝗺𝗲 𝗮 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗦𝗧𝗫-𝟭𝟭𝟱𝟬, a novel 𝘪𝘯 𝘷𝘪𝘷𝘰 epigenetic CRISPR therapy designed to deliver ultra-durable lowering of “bad cholesterol,” from a single dose, all without permanently altering the genome. This program is built on years of intentional and iterative engineering focused on improving the safety, specificity, potency, and durability of CRISPR medicines. 𝗕𝘂𝘁 𝘄𝗵𝗮𝘁 𝗲𝘅𝗰𝗶𝘁𝗲𝘀 𝗺𝗲 𝗺𝗼𝘀𝘁 𝗶𝘀 𝘄𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗰𝗼𝘂𝗹𝗱 𝗺𝗲𝗮𝗻 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗹𝗶𝗸𝗲 𝗺𝘆𝘀𝗲𝗹𝗳. As someone at high risk of ASCVD, like roughly one-third of adults in the U.S., I’ve spent a lot of time thinking about the burden patients carry. For a chronic disease like ASCVD, prevention is far from easy. Success depends on maintaining near-perfect adherence to pills or injections for decades. In the real world, that’s incredibly difficult and simply not practical for most people. The fact that ASCVD remains the leading cause of death globally, despite plenty of therapeutic choices, makes that painfully clear. 𝗧𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘀𝗵𝗼𝘂𝗹𝗱 𝗮𝘀𝗽𝗶𝗿𝗲 𝘁𝗼 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝗰𝗵𝗮𝗶𝗻𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘁𝗼 𝗹𝗶𝗳𝗲𝗹𝗼𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀. The vision behind STX-1150 is to provide year to decades of LDL-C lowering from a simple intervention, helping free patients from the constant burden of chronic treatment while more effectively reducing the risk of the world’s leading cause of death. The future is about empowering patients to take greater control of our own health destiny and preventing disease rather than waiting to treat it after catastrophe occurs. 𝗜 𝗯𝗲𝗹𝗶𝗲𝘃𝗲 𝗮 𝗻𝗲𝘄 𝗲𝗿𝗮 𝗼𝗳 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗶𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗵𝗼𝗿𝗶𝘇𝗼𝗻, 𝗼𝗻𝗲 𝘄𝗵𝗲𝗿𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗰𝗮𝗻 𝗱𝘂𝗿𝗮𝗯𝗹𝘆 𝗿𝗲𝘀𝗵𝗮𝗽𝗲 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗵𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗱 𝗮𝗹𝗹𝗼𝘄 𝘂𝘀 𝗮𝗹𝗹 𝘁𝗼 𝗹𝗶𝘃𝗲 𝗹𝗼𝗻𝗴𝗲𝗿, 𝗵𝗲𝗮𝗹𝘁𝗵𝗶𝗲𝗿 𝗹𝗶𝘃𝗲𝘀 𝘄𝗶𝘁𝗵 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗳𝗿𝗲𝗲𝗱𝗼𝗺. Extremely proud of the entire Scribe team for advancing this vision. Excited for what comes next.

Scribe Therapeutics @scribetx

a month ago

Announcing our first clinical trial. Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). Details🧵

1 4 11 5K 0

In @theheraldsun, Dr. Stephen Nicholls of @MonashVHI, Victorian Heart Hospital, and the PI leading Scribe's clinical trial shares his perspective on our epigenetic silencing drug STX-1150 and the need for improved therapies for cardiovascular disease. Links in thread ⬇️

#MyEAS2026

Scribe Therapeutics @scribetx

a month ago

STX-1150 is designed to epigenetically silence PCSK9 in the liver and deliver sustained LDL-C reduction after a single dose without permanently altering DNA, with the goal of enabling early and durable ASCVD risk reduction in patients. Link to our full announcement below ❤️‍🩹

1 0 3 555 0

#MyEAS2026

Scribe Therapeutics @scribetx

5 months ago

We're pleased to announce: 📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction 📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150

2 3 16 2K 0

Five years ago we sketched out the designs for our first epigenome editors. Proud to see those sketches move into the clinic. You can read more about the technology underpinning our epi-editors in this preprint we recently presented at ASGCT: biorxiv.org/content/10.648…

Scribe Therapeutics @scribetx

a month ago

Announcing our first clinical trial. Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). Details🧵

1 4 11 5K 0